quinazolines has been researched along with trametinib in 10 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 8 (80.00) | 24.3611 |
2020's | 2 (20.00) | 2.80 |
Authors | Studies |
---|---|
Adair, SJ; Bauer, TW; Borgman, CA; Chopivsky, ME; Cowan, CR; Gilmer, TM; Lindberg, JM; Lowrey, BT; Newhook, TE; Parsons, JT; Stelow, EB; Stokes, JB; Walters, DM | 1 |
Karakashev, SV; Reginato, MJ | 1 |
Belani, CP; Joshi, M; Liu, X; Miller, B; Rice, SJ | 1 |
Banno, E; Boku, N; De Velasco, MA; Fujita, Y; Mizukami, T; Nakajima, TE; Nishio, K; Sakai, K; Sogabe, S; Terashima, M; Togashi, Y; Tomida, S | 1 |
Cowan, N; Keiser, J | 1 |
Dar, AC; Dhawan, NS; Scopton, AP | 1 |
Beck, S; Frejno, M; Klaeger, S; Koch, H; Kuster, B; Ruprecht, B; Wilhelm, M | 1 |
Cronise, KE; Duval, DL; Gustafson, DL; Hernandez, BG | 1 |
Chanana, P; Dood, R; Haemmerle, M; Holland, EC; Lazar, AJ; Lyons, YA; Mangala, LS; Nagaraja, AS; Ravi, V; Siedel, JH; Sood, AK; Wagner, MJ; Wang, WL | 1 |
Kang, W; Kwon, JY; Lee, C; Lee, H; Maher, L; Michaud, M; Ning, G; Silva, M; Suh, YS; Zhang, C; Zhu, Q | 1 |
10 other study(ies) available for quinazolines and trametinib
Article | Year |
---|---|
Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epidermal growth factor receptor/HER2 inhibitor lapatinib.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; ErbB Receptors; Humans; Lapatinib; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Mice; Neoplasm Transplantation; Pancreatic Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Pyridones; Pyrimidinones; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2013 |
Hypoxia/HIF1α induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2.
Topics: Apoptosis; Breast Neoplasms; Cell Hypoxia; Cell Line; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Dual Specificity Phosphatase 2; Extracellular Signal-Regulated MAP Kinases; Female; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunoblotting; Kaplan-Meier Estimate; Lapatinib; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyridones; Pyrimidinones; Quinazolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction | 2015 |
Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Erlotinib Hydrochloride; G1 Phase; Humans; Indoles; Lung Neoplasms; MAP Kinase Signaling System; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Pyridones; Pyrimidinones; Quinazolines; Sulfonamides; Up-Regulation; Vemurafenib | 2015 |
EGFR and HER2 signals play a salvage role in MEK1-mutated gastric cancer after MEK inhibition.
Topics: Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Humans; Lapatinib; MAP Kinase Kinase 1; MAP Kinase Signaling System; Mutation; Phosphorylation; Protein Kinase Inhibitors; Pyridones; Pyrimidinones; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms | 2015 |
Repurposing of anticancer drugs: in vitro and in vivo activities against Schistosoma mansoni.
Topics: Animals; Antineoplastic Agents; Drug Repositioning; Inhibitory Concentration 50; Mice; Piperidines; Pyridones; Pyrimidinones; Quinazolines; Schistosoma mansoni; Schistosomiasis mansoni; Schistosomicides | 2015 |
Small molecule stabilization of the KSR inactive state antagonizes oncogenic Ras signalling.
Topics: Alleles; Allosteric Regulation; Cell Line; Enzyme Stability; Humans; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase Kinases; Models, Molecular; Mutation; Neoplasms; Oncogenes; Phosphorylation; Protein Binding; Protein Conformation; Protein Multimerization; Protein Serine-Threonine Kinases; Pyridones; Pyrimidinones; Quinazolines; raf Kinases; ras Proteins | 2016 |
Phosphoproteome Profiling Reveals Molecular Mechanisms of Growth-Factor-Mediated Kinase Inhibitor Resistance in EGFR-Overexpressing Cancer Cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Fibroblast Growth Factor 2; Gefitinib; Humans; Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Phosphopeptides; Protein Kinase Inhibitors; Proteome; Proteomics; Pyridones; Pyrimidinones; Quinazolines | 2016 |
Identifying the ErbB/MAPK Signaling Cascade as a Therapeutic Target in Canine Bladder Cancer.
Topics: Animals; Carcinoma, Transitional Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dog Diseases; Dogs; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; HT29 Cells; Humans; MAP Kinase Signaling System; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Quinazolines; Urinary Bladder Neoplasms; Vemurafenib | 2019 |
Combined VEGFR and MAPK pathway inhibition in angiosarcoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Hemangiosarcoma; Humans; MAP Kinase Signaling System; Mice; Mice, Nude; Prognosis; Pyridones; Pyrimidinones; Quinazolines; Transcriptome; Tumor Cells, Cultured; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2021 |
A novel treatment strategy for lapatinib resistance in a subset of HER2-amplified gastric cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mice; Mice, Inbred NOD; Mice, SCID; Pyridones; Pyrimidines; Pyrimidinones; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2021 |